Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4125.00
HEB's Cash to Debt is ranked higher than
59% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. HEB: 4125.00 )
Ranked among companies with meaningful Cash to Debt only.
HEB' s Cash to Debt Range Over the Past 10 Years
Min: 2.35  Med: 10000.00 Max: No Debt
Current: 4125
Equity to Asset 0.87
HEB's Equity to Asset is ranked higher than
78% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. HEB: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
HEB' s Equity to Asset Range Over the Past 10 Years
Min: 0.53  Med: 0.86 Max: 0.98
Current: 0.87
0.53
0.98
F-Score: 3
Z-Score: -12.87
M-Score: -3.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -12589.04
HEB's Operating margin (%) is ranked lower than
94% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. HEB: -12589.04 )
Ranked among companies with meaningful Operating margin (%) only.
HEB' s Operating margin (%) Range Over the Past 10 Years
Min: -12138.52  Med: -9214.09 Max: -915.51
Current: -12589.04
-12138.52
-915.51
Net-margin (%) -11334.93
HEB's Net-margin (%) is ranked lower than
94% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. HEB: -11334.93 )
Ranked among companies with meaningful Net-margin (%) only.
HEB' s Net-margin (%) Range Over the Past 10 Years
Min: -10816.67  Med: -6033.93 Max: -1149.22
Current: -11334.93
-10816.67
-1149.22
ROE (%) -64.51
HEB's ROE (%) is ranked lower than
70% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. HEB: -64.51 )
Ranked among companies with meaningful ROE (%) only.
HEB' s ROE (%) Range Over the Past 10 Years
Min: -89.44  Med: -52.90 Max: -20.44
Current: -64.51
-89.44
-20.44
ROA (%) -56.20
HEB's ROA (%) is ranked lower than
73% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. HEB: -56.20 )
Ranked among companies with meaningful ROA (%) only.
HEB' s ROA (%) Range Over the Past 10 Years
Min: -69.18  Med: -43.04 Max: -18.36
Current: -56.2
-69.18
-18.36
ROC (Joel Greenblatt) (%) -140.32
HEB's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. HEB: -140.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HEB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -386.32  Med: -243.28 Max: -135.24
Current: -140.32
-386.32
-135.24
EBITDA Growth (3Y)(%) 14.50
HEB's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. HEB: 14.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HEB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.8  Med: -5.85 Max: 16.1
Current: 14.5
-29.8
16.1
EPS Growth (3Y)(%) 11.50
HEB's EPS Growth (3Y)(%) is ranked higher than
69% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. HEB: 11.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HEB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.5  Med: -4.60 Max: 23.1
Current: 11.5
-40.5
23.1
» HEB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

HEB Guru Trades in Q4 2014

Jim Simons 254,400 sh (+245.18%)
» More
Q1 2015

HEB Guru Trades in Q1 2015

Jim Simons 672,500 sh (+164.35%)
» More
Q2 2015

HEB Guru Trades in Q2 2015

Jim Simons 1,143,900 sh (+70.10%)
» More
Q3 2015

HEB Guru Trades in Q3 2015

Jim Simons 1,397,800 sh (+22.20%)
» More
» Details

Insider Trades

Latest Guru Trades with HEB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 0.40
HEB's Forward P/E is ranked higher than
99% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 17.54 vs. HEB: 0.40 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.44
HEB's P/B is ranked higher than
76% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 2.68 vs. HEB: 1.44 )
Ranked among companies with meaningful P/B only.
HEB' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 1.34 Max: 12.12
Current: 1.44
0.18
12.12
P/S 199.62
HEB's P/S is ranked lower than
100% of the 1121 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. HEB: 199.62 )
Ranked among companies with meaningful P/S only.
HEB' s P/S Range Over the Past 10 Years
Min: 7  Med: 46.25 Max: 285
Current: 199.62
7
285
Current Ratio 4.20
HEB's Current Ratio is ranked lower than
53% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. HEB: 4.20 )
Ranked among companies with meaningful Current Ratio only.
HEB' s Current Ratio Range Over the Past 10 Years
Min: 1.36  Med: 5.42 Max: 44.82
Current: 4.2
1.36
44.82
Quick Ratio 3.80
HEB's Quick Ratio is ranked lower than
53% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. HEB: 3.80 )
Ranked among companies with meaningful Quick Ratio only.
HEB' s Quick Ratio Range Over the Past 10 Years
Min: 1.36  Med: 4.93 Max: 44.19
Current: 3.8
1.36
44.19
Days Inventory 131.73
HEB's Days Inventory is ranked lower than
54% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 124.17 vs. HEB: 131.73 )
Ranked among companies with meaningful Days Inventory only.
HEB' s Days Inventory Range Over the Past 10 Years
Min: 67  Med: 288.08 Max: 1827.33
Current: 131.73
67
1827.33
Days Payable 352.37
HEB's Days Payable is ranked higher than
92% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 57.61 vs. HEB: 352.37 )
Ranked among companies with meaningful Days Payable only.
HEB' s Days Payable Range Over the Past 10 Years
Min: 361.46  Med: 440.97 Max: 925.1
Current: 352.37
361.46
925.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.25
HEB's Price/Net Cash is ranked higher than
81% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: 6.04 vs. HEB: 3.25 )
Ranked among companies with meaningful Price/Net Cash only.
HEB' s Price/Net Cash Range Over the Past 10 Years
Min: 1.11  Med: 9.27 Max: 231.5
Current: 3.25
1.11
231.5
Price/Net Current Asset Value 3.25
HEB's Price/Net Current Asset Value is ranked higher than
85% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: 6.40 vs. HEB: 3.25 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
HEB' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.05  Med: 8.80 Max: 154.33
Current: 3.25
1.05
154.33
Price/Tangible Book 1.44
HEB's Price/Tangible Book is ranked higher than
92% of the 1048 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. HEB: 1.44 )
Ranked among companies with meaningful Price/Tangible Book only.
HEB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.74  Med: 6.68 Max: 154.33
Current: 1.44
0.74
154.33
Earnings Yield (Greenblatt) (%) -76.59
HEB's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. HEB: -76.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HEB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -76.59  Med: 498.60 Max: 2666.5
Current: -76.59
-76.59
2666.5

More Statistics

Revenue(Mil) $0
EPS $ -0.08
Beta-0.62
Short Percentage of Float0.06%
52-Week Range $0.06 - 0.29
Shares Outstanding(Mil)247.52

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil)
EPS($) -0.10 0.04 0.24 0.48
EPS without NRI($) -0.10 0.04 0.24 0.48

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HXB.Germany, HEB.Switzerland,
Hemispherx Biopharma Inc is a Delaware Corporation founded in the early 1970s. The Company is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Since its inception, it has established a foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. The Company owns and operates a 43,000 sq. ft. manufacturing facility in New Brunswick, NJ that produces Alferon and Ampligen. The Company operates in one segment, which performs research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection and, its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). As of December 31, 2013, the Company had 25 patents. Its potential competitors are among the largest pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities. The Company is subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research work.
» More Articles for HEB

Headlines

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

More From Other Websites
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 04 2016
8:31 am Hemispherx Biopharma introduces a voluntary stock purchase plan Feb 03 2016
Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value Feb 03 2016
Pre-Jonas flooding damages Phila. biotech firm's manufacturing plant Jan 25 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events Jan 22 2016
Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency... Jan 20 2016
Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency... Jan 20 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 14 2016
Philadelphia biotech firm discloses stock shares snafu Dec 31 2015
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 16 2015
Hemispherx Biopharma, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 11 2015
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 10 2015
HEMISPHERX BIOPHARMA INC Financials Dec 08 2015
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Nov 23 2015
Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2015 …... Nov 17 2015
Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2015 Nov 17 2015
HEMISPHERX BIOPHARMA INC Files SEC form 10-Q, Quarterly Report Nov 16 2015
Hemispherx Biopharma and myTomorrows Collaborate to Make Natural Alpha Interferon Available to... Nov 09 2015
Hemispherx Biopharma, Inc. – Value Analysis (NYSE MKT:HEB) : October 23, 2015 Oct 23 2015
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan... Oct 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK